Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE) [PDF]
, 1998 BACKGROUND: In the CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) trial, 1265 patients with refractory unstable angina were treated with abciximab or placebo, in addition to standard treatment from 16 to 24 hours
Klootwijk, A.P.J. (Peter) +4 more
core +2 more sources
Antiphospholipid syndrome and acute myocardial infarction: Treatment with thrombectomy and abciximab
Revista Portuguesa de Cardiologia, 2014 Antiphospholipid syndrome (APS) is an autoimmune coagulation disorder that manifests clinically as venous and arterial thrombosis, and may affect any tissue or organ. Coronary artery involvement, however, is very rare.
Vicens Martí +3 more
doaj +1 more source
Platelets, 2022 Platelet glycoprotein IIb/IIIa inhibitors (GPIs) have been part of the adjuvant treatment of acute coronary syndrome for years. However, real-life data regarding the efficacy and safety of GPIs under the current indications are lacking in the setting of ...
Pablo Revilla-Martí +8 more
doaj +1 more source
Soluble CD40 ligand in acute coronary syndromes [PDF]
, 2003 BACKGROUND: CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition ...
Boersma, H. (Eric) +6 more
core +1 more source
FLOW DIVERTER DEVICE IN THE ACUTE SETTING OF RUPTURED BLISTER LIKE ANEURYSM: A CASE REPORT [PDF]
Euromediterranean Biomedical Journal, 2021 Blister-like aneurysms (BLA) are a rare half-dome-shaped aneurysm, with a broad-based appearance, originating more often from a non-branching site of the supraclinoid internal carotid artery (ICA).
Cesare Gaglaiardo
doaj +1 more source
Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina [PDF]
, 2003 BACKGROUND: This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention.
Armstrong, P.W. (Paul) +9 more
core +3 more sources
Abciximab‐Associated Thrombocytopenia After Previous Tirofiban‐Related Thrombocytopenia [PDF]
, 2006 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90080/1/phco.26.3.423 ...
Dorsch, Michael P. +3 more
core +1 more source
BMC Cardiovascular Disorders, 2017 Background Thrombolysis is still used when primary angioplasty is delayed for a long time, but 25%–30% of patients require rescue angioplasty (RA). There are no established recommendations for antithrombotic management in RA.
José M. De la Torre Hernández +10 more
doaj +1 more source
Morphine Analgesia Pre-PPCI Is Associated with Prothrombotic State, Reduced Spontaneous Reperfusion and Greater Infarct Size [PDF]
, 2017 Schattauer GmbH Stuttgart.The emergency management of ST-elevation myocardial infarction (STEMI) involves treatment with dual-antiplatelet therapy (DAPT) and primary percutaneous coronary intervention (PPCI). Pain is generally treated with opiates, which
Farag, Mohamed +5 more
core +2 more sources
The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]
Vojnosanitetski Pregled, 2002 Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko +4 more
doaj +1 more source